BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
58.84
-0.15 (-0.25%)
At close: Jul 6, 2026, 4:00 PM EDT
58.79
-0.05 (-0.08%)
After-hours: Jul 6, 2026, 4:10 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $87.85. The average 1-year stock price forecast is 49.30% higher than the current stock price, while the lowest is $50 (-15.02%) and the highest is $120 (+103.94%).
Price Target: $87.85 (+49.30%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 14 | 14 |
| Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Hold | 5 | 5 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 26 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $104 | Buy | Maintains | $104 | +76.75% | Jul 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $50 | Hold | Reiterates | $50 | -15.02% | Jun 22, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Maintains $86 | Buy | Maintains | $86 | +46.16% | Jun 3, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $80 | Buy | Reiterates | $80 | +35.96% | May 29, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $68 | Hold | Maintains | $68 | +15.57% | May 24, 2026 |
Financial Forecast
Revenue This Year
3.90B
from 3.22B
Increased by 21.00%
Revenue Next Year
4.46B
from 3.90B
Increased by 14.50%
EPS This Year
4.94
from 3.15
Increased by 56.80%
EPS Next Year
6.46
from 4.94
Increased by 30.69%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.4B | ||
| Avg | 3.9B | ||
| Low | 3.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.8% | ||
| Avg | 21.0% | ||
| Low | 19.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.03 | ||
| Avg | 4.94 | ||
| Low | 4.86 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 59.7% | ||
| Avg | 56.8% | ||
| Low | 54.3% |